FDA approves Mimrylo for adults with polycythemia vera

Mimrylo is the first FDA-approved polycythemia vera treatment designed to mimic hepcidin, targeting the iron availability that drives excessive red blood cell production.

The FDA approved Mimrylo (rusfertide) for treatment of erythrocytosis in adults with polycythemia vera whose disease has not been adequately controlled with existing therapies.

By limiting the iron available for red blood cell production, the first-in-class therapy offers a new mechanism for controlling hematocrit and reducing the burden associated with excessive erythrocyte production.

Field	Content
Alert Type	Approval
Regulatory Authority	U.S. Food and Drug Administration (FDA)
Product	Mimrylo (rusfertide)
Indication	Treatment of erythrocytosis in adults with polycythemia vera
Therapy Area	Hematology / myeloproliferative neoplasms
Technology or Modality	Hepcidin mimetic
Geography	United States
What Happened	On 28 August 2026, the FDA approved Mimrylo (rusfertide) for adults with polycythemia vera, a rare blood disorder characterised by excessive red blood cell production.
Mechanism	Rusfertide mimics hepcidin, a hormone that regulates iron availability. By limiting the iron available for production of new red blood cells, the therapy helps reduce erythrocytosis.
Why It Matters	Mimrylo is the first approved treatment for polycythemia vera that mimics hepcidin, introducing a new mechanism of action for patients whose disease is not adequately controlled with existing therapies.
Supporting Context	Excess red blood cells can thicken the blood and increase the risk of complications including blood clots, stroke and heart attack.
Potential Impact	The approval provides clinicians with a new disease-control strategy that directly targets the biology supporting excessive red blood cell production.
Key Takeaway	FDA approval establishes Mimrylo as the first-in-class hepcidin-mimetic treatment for erythrocytosis in adults with polycythemia vera.
What to Watch	Uptake in patients requiring better hematocrit control and the therapy's positioning alongside existing cytoreductive and phlebotomy-based management strategies.
Primary Source	U.S. Food and Drug Administration
Relevant Date	28 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com